Related Experiment Video
Updated: Aug 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract
1Vincenzo Pansadoro Foundation, Clinic Pio XI, Rome, Italy. cstern@mclink.it
Abstract:
Cisplatin-based combination chemotherapy such as methotrexate, vinblastine, adriamycin and cisplatin produces durable improvements in survival in only a minority of patients. Therefore, other therapeutic options and strategies are clearly needed. Strategies include increasing the dose of chemotherapy, modifying the sequencing of chemotherapy, and new therapeutic agents. This paper reviews recent work on high-dose chemotherapy, currently available chemotherapeutic agents and combinations, with an emphasis on gemcitabine and the taxanes. New strategies such as monoclonal antibody therapy and molecular targeted small molecule therapy are becoming a reality in the treatment of many diseases. The rationale for using epidermal growth factor receptor targeted therapies is also reviewed.
More Related Videos
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Published on: November 22, 2019
04:45Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode
Published on: March 20, 2026
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Kidney Transplant II: Surgical Procedure